Frequently asked questions

Drug development teams with a real translational or clinical question and the authority to act on the answer. We work with large pharma, mid-cap pharma, biotech, and well-funded startups. The question and the team set the bar, not the company.

We accept partners on a rolling basis. Engagements are scoped one at a time, and the work is high-touch enough that we keep our number of concurrent runs deliberately small.

Each engagement is a defined fixed term, with scope and milestones agreed at kickoff. Projects vary by archetype—some run in weeks, others in months. We will be specific with you during discovery.

Nothing. The Ingenix Biological Reasoning Engine is operated by our team on your question and data—partners don’t integrate the engine, install software, or train internal scientists to operate anything. What you receive are project outputs with the reasoning trace behind each.

During discovery, we work with your scientific lead to define the question precisely, define the deliverables, identify the data needed, and set milestones. We do not start the work until both sides agree on what the project is—and what it isn’t.

It depends on the question. Often less than partners expect. The engine reasons across scientific literature, clinical data, omics, pathways, structures, and more—most of what it needs is already accessible to us. Partner-specific data (internal omics, preclinical readouts, trial data) is only required if the question requires it. We agree on what’s needed and how it will be handled before any data moves.

A team of three is assigned for the duration of the engagement. It consists of a named project lead, who is your single point of contact, plus a lead scientist who works the engine, and an executive sponsor from Ingenix leadership.

Yes. The engine is built to deliver negative findings as readily as positive ones—that is, recommendations against an action, not only in favour of one. Each finding arrives with the reasoning trace substantiating it, so rather than receiving a verdict without context, your scientists can interrogate the basis for the recommendation. Part of the value we bring lies in shielding a decision from the impact of false signals.

You do.
Everything the engine produces for your project belongs to you. This includes all outputs, analyses, ranked hypotheses, mechanism narratives, derived datasets, and recommendations. It is your program. We have no claim on its outputs, do not assert co-ownership, and do not use any of your results to inform other partners’ work.
Any data you share with us during the engagement remains yours. We process it under the terms of our Data Processing Agreement. We do not acquire rights to it, we do not use it for any purpose other than your project, and we do not retain it beyond the defined engagement scope.
The engine, the models, the methods, and the architectural improvements we make over time belong to Ingenix. This constitutes our asset. Your confidential data and your project IP are not used to train shared engine components.

Terms are negotiated during discovery and are designed to reflect early partnership rather than standard commercial engagement. We will be specific with you once we understand the project.

One of three things: continuation under standard commercial terms, a defined extension if the project is mid-stride, or a clean off-board. All three outcomes are considered at kickoff so the end of the engagement is never a surprise.

Ingenix is ISO/IEC 27001, 27017, and 27018 certified, as well as AI Act compliant. Partner data is processed within our secure environment under controls audited against the standard, with data residency, retention, access, and deletion documented before any data moves. We will not use partner data to train shared engine components without explicit permission negotiated separately.

Yes. Mutual confidentiality applies from the moment we begin discussing your project and is in effect both before a formal agreement is in place and after its cessation.

Yes, by mutual agreement. We work with partners to support publication of project outputs when the partner wants to share them—be it internally, at conferences, or in peer-reviewed work.

Yes. Publication of QAP work—case studies, benchmark contributions, and scientific outputs—is at Ingenix’s discretion and it is part of the program structure. The favourable QAP commercial framework reflects this. Timing, anonymisation, and any commercially sensitive details are agreed at scoping so partners know what to expect.

Submit the application form, which takes about ten minutes. We will respond within two weeks.

You will hear from us. We will briefly share why. Sometimes the answer will be “not yet”—as circumstances change and programs evolve we will be able to re-evaluate applications.

We work globally. Specific data handling and contracting requirements vary by jurisdiction; we address those during discovery.